Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations

BACKGROUND: Selpercatinib (LOXO-292) and pralsetinib (BLU-667) are highly potent RET-selective protein tyrosine kinase inhibitors (TKIs) for treating advanced RET-altered thyroid cancers and non-small-cell lung cancer (NSCLC). It is critical to analyze RET mutants resistant to these drugs and unrave...

Descripción completa

Detalles Bibliográficos
Autores principales: Subbiah, V., Shen, T., Terzyan, S. S., Liu, X., Hu, X., Patel, K. P., Hu, M., Cabanillas, M., Behrang, A., Meric-Bernstam, F., Vo, P. T. T., Mooers, B. H. M., Wu, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883646/
https://www.ncbi.nlm.nih.gov/pubmed/33161056
http://dx.doi.org/10.1016/j.annonc.2020.10.599

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883646/
https://www.ncbi.nlm.nih.gov/pubmed/33161056
http://dx.doi.org/10.1016/j.annonc.2020.10.599

Ejemplares similares